Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
Suhler
Eric B
EB
Smith
Justine R
JR
Giles
Tracy R
TR
Lauer
Andreas K
AK
Wertheim
Michael S
MS
Kurz
Daryl E
DE
Kurz
Paul A
PA
Lim
Lyndell
L
Mackensen
Friederike
F
Pickard
Terri D
TD
Rosenbaum
James T
JT
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab